Replimune to Present at the 2025 Jefferies Global Healthcare Conference
Replimune Group (NASDAQ: REPL), a clinical-stage biotech company focused on developing novel oncolytic immunotherapies, has announced its participation in the 2025 Jefferies Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Replimune Group (NASDAQ: REPL), a clinical-stage biotech company focused on developing novel oncolytic immunotherapies, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 4:20 PM ET. Investors can access the live webcast through Replimune's website investor section, with a replay available for 30 days after the event.
Details
News Market Reaction – REPL
The recorded move for REPL in the trading session of this news was +11.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.